Response to everolimus of a progressive plexiform neurofibroma in Neurofibromatosis type 1

Pediatr Int. 2020 Jul;62(7):857-859. doi: 10.1111/ped.14183. Epub 2020 Jul 6.

Maria Elena Mateos^{1

2}, Eduardo López-Laso^{2

3}, Josefina Vicente⁴, Rosa Ortega^{2

5}, Fernando Vázquez^{2

6}, Juan Luis Pérez-Navero^{1

2}

¹ Pediatric Oncology Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain.
² Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Reina Sofia University Hospital, Córdoba, Spain.
³ Neuropediatric Unit, Department of Pediatrics, Reina Sofia University Hospital, Córdoba, Spain.
⁴ Pediatric Radiology Unit, Department of Radiology, Reina Sofia University Hospital, Córdoba, Spain.
⁵ Department of Pathology, Reina Sofia University Hospital, Córdoba, Spain.
⁶ Department of Pediatric Surgery, Reina Sofia University Hospital, Córdoba, Spain.

No abstract available

Keywords: everolimus; mammalian target of rapamycin; neurofibromatosis type 1; plexiform neurofibroma; therapeutics.

Publication types